In fact, a decrease in CYP3A4 expression at the microsomal fraction of clinical hepatomas has been reported [34] and when the prognosis of hepatoma patients was compared between the high and low expression groups of the CYP3A4 gene, the survival rate was found to be higher in the high expression group, as in the case of MAOB (see Supplementary Figure S3B). This evidence concerns the gene CYP3A4 and hepatocellular carcinoma.